OSE Immunotherapeutics
Faculté de Médecine
1, rue Gaston Veil
Nantes
44000
France
Tel: 33-0-2-40-41-28-34
Website: http://ose-immuno.com/
Email: contact@ose-immuno.com
138 articles with OSE Immunotherapeutics
-
OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression
5/18/2022
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the first participant has been dosed in a Phase 1 Study of VEL-101/FR104 [NCT05238493], a study sponsored and conducted by its partner in transplantation, Veloxis Pharmaceuticals, Inc., an Asahi Kasei company.
-
OSE Immunotherapeutics To Present at ‘Immuno-Oncology Summit Europe’ and at ‘Tumor Myeloid-Directed Therapies Summit’ In London and Boston
5/11/2022
OSE Immunotherapeutics SA has been invited to provide an update on its R&D programs in immuno-oncology at two dedicated international conferences in May and June.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
OSE Immunotherapeutics Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy
5/2/2022
OSE Immunotherapeutics SA announced the grant of a new patent from the European Patent Office strengthening the protection covering its novel myeloid cell immune checkpoint target, CLEC-1, and its use in cancer treatment.
-
OSE Immunotherapeutics Invited to Present Preclinical Data on its PD-1/IL-7 Bifunctional Program BiCKI®-IL-7 Cancer Immunotherapy
4/4/2022
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Company is invited to present the latest progress on its bispecific antibody checkpoint inhibitor BiCKI® platform, and in particular on its bifunctional therapy targeting PD-1 and the Interleukin-7 (IL-7) cytokine, BiCKI®-IL-7, during a plenary oral presentation in an educational session dedicated to immunocytokines at the American Association Cancer for Research (AACR) annual meeting.
-
OSE Immunotherapeutics Reports 2021 Financial Results: Major Progress on its Clinical Programs and a Solid Cash Position to Support its Activities
3/30/2022
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) reported its consolidated annual financial results for 2021 and provided an update on key achievements, as well as the Company’s outlook for 2022 for its immunotherapies in immuno-oncology and immuno-inflammation.
-
OSE Immunotherapeutics Receives First Notice of Allowance for a US Patent Covering Anti-PD1 Monoclonal Antibody OSE-279 And its Use in Cancer Treatment
3/21/2022
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces that the United States Patent and Trademark Office (USPTO) has issued a first notice of allowance for a patent application covering OSE-279, an anti-PD1 monoclonal antibody, and its use in cancer treatment.
-
OSE Immunotherapeutics Provides Positive Long Term Memory Responses with CoVepiT, its T Lymphocyte Multi-Target Anti-COVID Vaccine
3/16/2022
OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announces positive analysis of the long-term immune T cell responses of CoVepiT, its prophylactic vaccine candidate against COVID-19, with positive immunological results obtained at 6 months on T cell memory response in the vaccinated subjects. In parallel, the resolution of local indurations related to T cell mechanism of action (1) and the good safety profile were confirmed.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses from the Phase 1 Clinical Trial with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors
3/9/2022
OSE Immunotherapeutics, announced that early biomarker analyses from the ongoing Phase 1 clinical trial with SIRPα inhibitor BI 765063 in patients with advanced solid tumors have been selected for presentation in an in-person poster session at the American Association Cancer for Research annual meeting to be held on April 8 – 13, 2022 in New Orleans, Louisiana.
-
OSE Immunotherapeutics Announces Appointment of Alexandre Lebeaut as an Independent Member of the Board of Directors
2/18/2022
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the appointment by cooptation of Alexandre Lebeaut as an independent Director of the Company*.
-
OSE Immunotherapeutics is Pleased to Announce that Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, has Obtained FDA Fast-Track Designation for CD28 Antagonist VEL-101/FR104
2/17/2022
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, has obtained fast track designation from the U.S. Food & Drug Administration (FDA) for VEL-101/FR104, a novel investigational maintenance immunosuppressive agent being developed for prophylaxis of renal allograft rejection in recipients of kidney transplants.
-
It was a relatively quiet week for clinical trial announcements. Here’s a look.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Transfer of OSE Immunotherapeutics’ Shares from Compartment C to Compartment B of Euronext Paris from January 31, 2022
2/1/2022
OSE Immunotherapeutics SA announced that its shares have been transferred from compartment C to compartment B of Euronext Paris.
-
OSE Immunotherapeutics Announces Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104
1/31/2022
OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE), today announced acceptance of the IND obtained by Veloxis Pharmaceuticals, Inc. from the Food & Drug Administration (FDA) for a clinical trial with VEL-101/FR104.
-
OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients
1/25/2022
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Japanese Patent Office has issued the notice of allowance for a new patent covering Tedopi ® , a combination of neoepitopes, for use after failure with PD-1 or PD-L1 immune checkpoint inhibitor treatment in HLA-A2 positive cancer patients.
-
BioSpace Movers & Shakers, Jan. 21
1/21/2022
Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth. -
OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles
1/17/2022
OSE Immunotherapeutics SA announced the departure of Alexis Peyroles as Chief Executive Officer.
-
BioSpace Movers & Shakers, Dec. 24
12/24/2021
With all eyes on a new year, life sciences companies and organizations are making last-minute appointments to strengthen their leadership teams and board with these Movers & Shakers.